Insider Selling: Insulet Co. (NASDAQ:PODD) Director Sells $501,875.00 in Stock

Insulet Co. (NASDAQ:PODD) Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Insulet Stock Down 0.6 %

PODD stock opened at $258.75 on Friday. The firm’s 50-day moving average is $271.69 and its two-hundred day moving average is $258.53. The company has a market capitalization of $18.17 billion, a price-to-earnings ratio of 44.69, a price-to-earnings-growth ratio of 3.62 and a beta of 1.29. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The firm had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. On average, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

PODD has been the subject of a number of recent research reports. Raymond James reaffirmed an “outperform” rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. TD Cowen increased their price target on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. boosted their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research report on Thursday, December 12th. Finally, StockNews.com downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Integrated Wealth Concepts LLC raised its position in Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after acquiring an additional 42 shares in the last quarter. Horizon Investments LLC lifted its stake in Insulet by 3.1% during the fourth quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC lifted its stake in Insulet by 1.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after purchasing an additional 43 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in Insulet by 2.3% during the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after buying an additional 47 shares in the last quarter. Finally, Graypoint LLC grew its position in Insulet by 5.3% in the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 47 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.